GlassScriptPhysician profile
Pradeep C Jolly
NPI 1023096823
$12,508.52
in general payments reported to CMS, 2019-2025
40 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $4,442 · 2021: $2,857 · 2022: $152 · 2023: $129 · 2024: $2,829 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558 · Consulting Fee: $1,800 · Education: $61.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.04 |
| Consulting Fee | $1,800.00 |
| Education | $61.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,789.01 | 2019-2025 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $2,877.03 | 2021-2025 | Opdualag |
| Karyopharm Therapeutics INC. | $1,300.00 | 2021 | |
| Pfizer INC. | $693.66 | 2020-2025 | |
| Exelixis INC. | $412.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $265.85 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.46 | 2023-2025 | Lynparza, Enhertu, Tagrisso |
| Celgene Corporation | $180.54 | 2024-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $130.37 | 2022-2025 | |
| Advanced Accelerator Applications | $125.23 | 2019 | |
| Merck Sharp & Dohme LLC | $115.45 | 2024-2025 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $102.72 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Daiichi Sankyo INC. | $102.59 | 2024-2025 | Enhertu, Vanflyta |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2021 | |
| Array Biopharma INC | $94.31 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $90.73 | 2022-2025 | Talvey, Darzalex, Rybrevant |
| Eisai INC. | $90.11 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.28 | 2019-2024 | Vpriv |
| Astellas Pharma US INC | $77.10 | 2020-2024 | Padcev |
| Lilly USA, LLC | $61.27 | 2024 | Jaypirca, Verzenio |
| Adc Therapeutics America, INC. | $58.64 | 2025 | |
| Abbvie INC. | $56.39 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.45 | 2024-2025 | |
| Immunocore Limited | $41.53 | 2024-2025 | Kimmtrak |
| Genentech USA, INC. | $32.72 | 2019-2024 | Tecentriq, Venclexta, Rozlytrek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.01 | 2025 | |
| Tempus Ai, INC | $30.49 | 2024 | |
| Gilead Sciences, INC. | $30.34 | 2025 | Trodelvy |
| Beigene USA, INC. | $24.24 | 2024 | Brukinsa |
| Coherus Oncology, INC. | $23.53 | 2025 | Udenyca |
| Puma Biotechnology, INC. | $23.38 | 2024 | |
| Mirati Therapeutics, INC. | $22.44 | 2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $21.47 | 2024 | Qinlock |
| Sumitomo Pharma America, INC. | $21.46 | 2025 | Orgovyx |
| Acrotech Biopharma INC. | $21.41 | 2025 | Beleodaq |
| Agios Pharmaceuticals, INC. | $19.59 | 2025 | Pyrukynd |
| Verity Pharmaceuticals INC. | $18.81 | 2023 | Trelstar |
| Sobi, INC | $18.63 | 2025 | |
| Dova Pharmaceuticals | $14.86 | 2019 | |
| Pharmaand Gmbh | $13.34 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Jolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.